Oddo BHF Asset Management Sas Sells 7,794 Shares of Alnylam Pharmaceuticals, Inc. $ALNY

Oddo BHF Asset Management Sas cut its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 20.6% during the fourth quarter, HoldingsChannel.com reports. The firm owned 30,133 shares of the biopharmaceutical company’s stock after selling 7,794 shares during the period. Oddo BHF Asset Management Sas’ holdings in Alnylam Pharmaceuticals were worth $11,982,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also modified their holdings of the company. Caitong International Asset Management Co. Ltd bought a new stake in shares of Alnylam Pharmaceuticals during the third quarter valued at approximately $29,000. HM Payson & Co. bought a new stake in shares of Alnylam Pharmaceuticals during the fourth quarter valued at approximately $27,000. Ameriflex Group Inc. bought a new stake in shares of Alnylam Pharmaceuticals during the third quarter valued at approximately $32,000. Golden State Wealth Management LLC increased its position in shares of Alnylam Pharmaceuticals by 100.0% during the fourth quarter. Golden State Wealth Management LLC now owns 72 shares of the biopharmaceutical company’s stock valued at $29,000 after purchasing an additional 36 shares during the period. Finally, Aster Capital Management DIFC Ltd bought a new stake in shares of Alnylam Pharmaceuticals during the third quarter valued at approximately $36,000. 92.97% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities analysts have commented on the company. Citigroup assumed coverage on Alnylam Pharmaceuticals in a research note on Tuesday, May 19th. They issued a “buy” rating and a $380.00 price objective on the stock. Wells Fargo & Company boosted their price objective on Alnylam Pharmaceuticals from $376.00 to $377.00 and gave the stock an “equal weight” rating in a research note on Friday, May 1st. HC Wainwright reaffirmed a “buy” rating and set a $510.00 price target on shares of Alnylam Pharmaceuticals in a research note on Thursday, June 4th. Canaccord Genuity Group upped their price target on Alnylam Pharmaceuticals from $415.00 to $429.00 and gave the company a “buy” rating in a research note on Tuesday, February 17th. Finally, Chardan Capital reaffirmed a “buy” rating and set a $425.00 price target on shares of Alnylam Pharmaceuticals in a research note on Wednesday, March 25th. Two research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and six have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $463.13.

Alnylam Pharmaceuticals Trading Up 1.8%

NASDAQ ALNY opened at $287.80 on Tuesday. The stock has a 50-day simple moving average of $303.69 and a 200 day simple moving average of $342.04. The company has a market capitalization of $38.42 billion, a PE ratio of 78.63 and a beta of 0.29. The company has a current ratio of 3.13, a quick ratio of 3.06 and a debt-to-equity ratio of 0.94. Alnylam Pharmaceuticals, Inc. has a 12 month low of $281.36 and a 12 month high of $495.55.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings data on Thursday, April 30th. The biopharmaceutical company reported $1.99 EPS for the quarter, beating analysts’ consensus estimates of $0.87 by $1.12. The business had revenue of $1.17 billion during the quarter, compared to the consensus estimate of $1.12 billion. Alnylam Pharmaceuticals had a return on equity of 85.76% and a net margin of 11.72%.The firm’s revenue was up 96.4% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.44) earnings per share. Research analysts forecast that Alnylam Pharmaceuticals, Inc. will post 7.47 EPS for the current year.

Insider Transactions at Alnylam Pharmaceuticals

In related news, Director David E. I. Pyott sold 3,830 shares of the company’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $299.18, for a total value of $1,145,859.40. Following the completion of the sale, the director owned 1,582 shares in the company, valued at approximately $473,302.76. This represents a 70.77% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Melissa Mclaughlin sold 2,286 shares of the company’s stock in a transaction dated Monday, April 6th. The shares were sold at an average price of $330.42, for a total value of $755,340.12. Following the completion of the sale, the insider owned 9,443 shares of the company’s stock, valued at $3,120,156.06. This represents a 19.49% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 7,740 shares of company stock valued at $2,420,214 in the last quarter. 0.86% of the stock is currently owned by corporate insiders.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.